Detail akcie Arct Therap Hldg Rg online

Business Summary: Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Arcturus Therapeutics Holdings Inc revenues decreased 42% to $74.8M. Net loss decreased 28% to $36.7M. Revenues reflect Revenue Sales of Goods & Services decrease of 45% to $64.1M, Grant revenue decrease of 12% to $10.7M. Lower net loss reflects Company’s nucleic acid-focused technology segment loss decrease of 28% to $45M.